Follow
Brandon A. Mahal
Brandon A. Mahal
Vice Chair and Residency Program Director, University of Miami Department of Radiation Oncology
Verified email at med.miami.edu
Title
Cited by
Cited by
Year
Association of black race with prostate cancer–specific and other-cause mortality
RT Dess, HE Hartman, BA Mahal, PD Soni, WC Jackson, MR Cooperberg, ...
JAMA oncology 5 (7), 975-983, 2019
4182019
Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies
WC Jackson, J Silva, HE Hartman, RT Dess, AU Kishan, WH Beeler, ...
International Journal of Radiation Oncology* Biology* Physics 104 (4), 778-789, 2019
3292019
Safety of combining radiotherapy with immune-checkpoint inhibition
WL Hwang, LRG Pike, TJ Royce, BA Mahal, JS Loeffler
Nature reviews Clinical oncology 15 (8), 477-494, 2018
2612018
Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015
BA Mahal, S Butler, I Franco, DE Spratt, TR Rebbeck, AV D’Amico, ...
Jama 321 (7), 704-706, 2019
2362019
Integrated analysis of genetic ancestry and genomic alterations across cancers
J Yuan, Z Hu, BA Mahal, SD Zhao, KH Kensler, J Pi, X Hu, Y Zhang, ...
Cancer cell 34 (4), 549-560. e9, 2018
2202018
Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States
BA Mahal, PJ Catalano, RI Haddad, GJ Hanna, JI Kass, JD Schoenfeld, ...
Cancer epidemiology, biomarkers & prevention 28 (10), 1660-1667, 2019
1982019
Prostate cancer radiation therapy recommendations in response to COVID-19
NG Zaorsky, BY James, SM McBride, RT Dess, WC Jackson, BA Mahal, ...
Advances in radiation oncology 5, 26-32, 2020
1882020
Marital status and head and neck cancer outcomes
G Inverso, BA Mahal, AA Aizer, RB Donoff, NG Chau, RI Haddad
Cancer 121 (8), 1273-1278, 2015
1702015
Association of androgen deprivation therapy with depression in localized prostate cancer
KT Dinh, G Reznor, V Muralidhar, BA Mahal, MD Nezolosky, TK Choueiri, ...
Journal of Clinical Oncology 34 (16), 1905-1912, 2016
1642016
The Lancet Commission on prostate cancer: planning for the surge in cases
ND James, I Tannock, J N'Dow, F Feng, S Gillessen, SA Ali, B Trujillo, ...
The Lancet 403 (10437), 1683-1722, 2024
1632024
A systematic review of the evidence for the decipher genomic classifier in prostate cancer
NK Jairath, A Dal Pra, R Vince Jr, RT Dess, WC Jackson, JJ Tosoian, ...
European urology 79 (3), 374-383, 2021
1562021
The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors
LRG Pike, A Bang, BA Mahal, A Taylor, M Krishnan, A Spektor, ...
International Journal of Radiation Oncology* Biology* Physics 103 (1), 142-151, 2019
1522019
Prostate cancer–specific mortality across Gleason scores in black vs nonblack men
BA Mahal, RA Berman, ME Taplin, FW Huang
Jama 320 (23), 2479-2481, 2018
1522018
Racial disparities in B lack men with prostate cancer: A literature review
JW Lillard Jr, KA Moses, BA Mahal, DJ George
Cancer 128 (21), 3787-3795, 2022
1462022
Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer
KT Dinh, BA Mahal, DR Ziehr, V Muralidhar, YW Chen, VB Viswanathan, ...
The Journal of urology 194 (2), 343-349, 2015
1422015
Racial differences in genomic profiling of prostate cancer
BA Mahal, M Alshalalfa, KH Kensler, I Chowdhury-Paulino, P Kantoff, ...
New England Journal of Medicine 383 (11), 1083-1085, 2020
1112020
Clinical and genomic characterization of low–prostate-specific antigen, high-grade prostate cancer
BA Mahal, DD Yang, NQ Wang, M Alshalalfa, E Davicioni, V Choeurng, ...
European urology 74 (2), 146-154, 2018
1072018
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
LA Gharzai, R Jiang, D Wallington, G Jones, S Birer, N Jairath, ...
The Lancet Oncology 22 (3), 402-410, 2021
1032021
Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups
BA Mahal, AA Aizer, DR Ziehr, AS Hyatt, JD Sammon, M Schmid, ...
Urology 84 (2), 386-392, 2014
982014
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
DE Spratt, M Alshalalfa, N Fishbane, AB Weiner, R Mehra, BA Mahal, ...
Clinical Cancer Research 25 (22), 6721-6730, 2019
972019
The system can't perform the operation now. Try again later.
Articles 1–20